Aim:

To evaluate the efficacy and tolerability of vardenafil, a phosphodiesterase type-5 (PDE-5) inhibitor, in men of Asian ethnicity with erectile dysfunction (ED).

Methods:

In this prospective, double-blind, multinational study, Asian men were randomized to receive vardenafil (10 mg) or placebo (4:1 ratio) for 12 weeks. The primary efficacy variables were the International Index of Erectile Function erectile function domain (IIEF-EF), and Sexual Encounter Profile (SEP) questions related to penetration and intercourse completion. Significant mean improvements were required in all three measures to show positive benefits of vardenafil treatment. Secondary efficacy variables included the Global Assessment Question (GAQ) on erection improvement.

Results:

Least-squares mean baseline IIEF-EF domain scores (vardenafil 14.6, placebo 13.4) were consistent with moderate ED. After 12 weeks, vardenafil treatment was associated with significant increases from the baseline in IIEF-EF domain scores compared with the placebo (22.4 vs. 14.3; P < 0.001). Vardenafil was associated with significant improvements from baseline in least squares (LS) mean success rates for SEP-2 (vardenafil 82.2 vs. placebo 43.6; P < 0.001) and SEP-3 (vardenafil 66.1 vs. placebo 24.0; P < 0.001). Positive GAQ responses were reported by 81.8% of vardenafil recipients vs. 24.3% of placebo recipients. Adverse events were reported by 25.4% of the vardenafil group, the majority mild and transient.

Conclusion:

Vardenafil (10 mg) is a highly effective and well-tolerated treatment for moderate ED in Asian men. These results add to the increasing amount of data demonstrating the safety and efficacy of vardenafil for the treatment of ED in a range of patient populations.

References

1. Sanchez-Cruz JJ, Cabrera-Leon A, Martin-Morales A, Fernandez A, Burgos R, Rejas J. Male erectile dysfunction and health-related quality of life. Eur Urol 2003; 44: 245–53. | Article | PubMed | ISI | ChemPort |
2. Martin-Morales A, Meijide F, Garcia N, Artes M, Munoz A. Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. J Sex Med 2007; 4: 440–7. | Article | PubMed | ChemPort |
3. Mallis D, Moisidis K, Kirana PS, Papaharitou S, Simos G, Hatzichristou D. Moderate and severe erectile dysfunction equally affects life satisfaction. J Sex Med 2006; 3: 442–9. | Article | PubMed |
4. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 (Suppl 4): S6–S11. | Article | PubMed | ISI |
5. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50–6. | Article | PubMed |
6. Lin CS, Lin G, Lue TF. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med 2005; 2: 478–91. | Article | PubMed | ChemPort |
7. Eardley I. Vardenafil: a new oral treatment for erectile dysfunction. Int J Clin Pract 2004; 58: 801–6. | Article | PubMed | ChemPort |
8. Montorsi F, Salonia A, Briganti A, Barbieri L, Zanni G, Suardi N, et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol 2005; 47: 612–21. | Article | PubMed | ISI | ChemPort |
9. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006; 3: 883–91. | Article | PubMed | ChemPort |
10. Valiquette L, Montorsi F, Auerbach S; Vardenafil Study Group. First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. Int J Clin Pract 2006; 60: 1378–85. | Article | PubMed | ChemPort |
11. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I; Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006; 3: 1037–49. | Article | PubMed | ISI | ChemPort |
12. Nehra A, Grantmyre J, Nadel A, Thibonnier M, Brock G. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005; 173: 2067–71. | Article | PubMed | ChemPort |
13. Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, et al; Vardenafil Study Group. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006; 66: 210–6. | Article | PubMed | ISI | ChemPort |
14. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192–9. | Article | PubMed | ISI | ChemPort |
15. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763–71. | PubMed | ISI | ChemPort |
16. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al; Vardenafil Study Group. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a ran domized, dou bleblin d, 2 6–week placebo-controlled pivotal trial. Urology 2003; 61 (Suppl): 8–14. | Article | PubMed | ISI |
17. Cheng E. Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction-results from 30,010 US Patients. J Sex Med 2007; 4: 432–9. | Article | PubMed | ChemPort |
18. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44: 1083–105. | Article | PubMed | ChemPort |
19. Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 2005; 37: 327–78. | Article | PubMed | ISI | ChemPort |
20. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271–94. | Article | PubMed | ISI | ChemPort |
21. Crimmel AS, Conner CS, Monga M. Withered Yang: a review of traditional Chinese medical treatment of male infertility and erectile dysfunction. J Androl 2001; 22: 173–82. | PubMed | ChemPort |
22. Nicolosi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003; 61: 201–6. | Article | PubMed | ISI |
23. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–30. | Article | PubMed | ISI | ChemPort |
24. Chen KK, Paick JS, Ishii N. The efficacy and safety of vardenafil in East Asian men with erectile dysfunction. J Sex Med 2007; 4: 753–61. | Article | PubMed | ChemPort |
25. Tan HM, Low WY, Ng CJ, Chen KK, Sugita M, Ishii N, et al. Prevalence and correlates of erectile dysfunction (ED) and treatment seeking for ED in Asian men: the Asian Men's Attitudes to Life Events and Sexuality (Asian MALES) study. J Sex Med 2007; 4: 1582–92. | Article | PubMed |
26. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002; 14: 226–44. | Article | PubMed | ISI | ChemPort |
27. Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez-Vela L, et al; Vardenafil Study Site Investigators. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006; 163: 79–87. | Article | PubMed | ISI |
28. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T; Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003 26: 777–83. | Article | PubMed | ISI | ChemPort |
29. Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003 170: 1278–83. | Article | PubMed | ISI | ChemPort |

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.